Camrelizumab(SHR-1210) Combined With GEMOX in Patients With Relapsed or Refractory Hodgkin Lymphoma
Clinical trial NCT04239170 · UNKNOWN
Trial details
- NCT number
- NCT04239170
- Sponsor
- Peking University
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-01-01
- Primary completion
- 2022-12-01
- Enrollment
- 84
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.